Guangdong Provincial People's Hospital and EnkayCell Therapeutics Sign Research Collaboration Agreement to Advance NK Cell Therapy for Autoimmune Diseases

Nov 26, 2024 10:25 CST Updated 10:25

NK CellTech

Immune Cell Therapy Developer

November 22, 2024At the Great Hall of Guangzhou Baiyun International Conference Center, Professor Yu Xueqing, President of Guangdong Provincial People's Hospital, and Academician Tian Zhigang, founder of Shanghai EnCay Cell Technology Co., Ltd. (hereinafter referred to as "EnCay Therapeutics"), signed a research cooperation agreement on behalf of both parties. This agreement aims to deepen the collaboration between the two parties.In the field of autoimmune diseases such as lupus nephritisFurther cooperation and expansion of NK cell therapy.

Professor Xueqing Yu (left), President of Guangdong Provincial People's Hospital & Academician Zhigang Tian (right), Enkaicell

With the aggravation of population aging and the acceleration of life pace, autoimmune diseases have become one of the significant factors affecting human health. As an autoimmune disease, lupus nephritis is difficult to treat with a high recurrence rate, seriously impacting patients' quality of life. The research collaboration between Enkaicai Pharmaceuticals and Guangdong Provincial People's Hospital will focus on pooling complementary resources from both sides to explore more effective treatment methods, providing patients with safer and more efficient therapeutic options.

At the signing ceremony,Dean Xueqing Yu"The Guangdong Provincial People's Hospital has always been committed to advancing medical science and technology innovation and enhancing medical service capabilities. This collaboration with Enkaicel Pharmaceuticals not only aligns with our hospital's development direction but also brings new hope to patients with autoimmune diseases in China and even globally."

FieldAcademician ZhigangEmphasized: "We are highly honored to establish a cooperative relationship with a high-level medical institution like Guangdong Provincial People's Hospital. Through this collaboration, Enkecell will fully leverage our expertise in NK cell technology, combined with the extensive clinical resources and experience of Guangdong Provincial People's Hospital, to accelerate the research and application of NK cell therapy in treating autoimmune diseases."

The signing ceremony was also attended by several renowned experts and scholars, including Professor Yao Zhibin, President of the Guangdong Medical Association; Professor Cai Guangyan, Chairman of the Chinese Society of Nephrology; Professor Chen Jianghua, former Chairman; Professor Yang Rongyuan, Party Committee Deputy Secretary of Guangdong Provincial People's Hospital; Professor Li Xin, Vice President; and Professor Zhang Cai, Vice President of Science and Strategy at Enkaicell. They highly praised this collaboration, considering it an important milestone in advancing the development of China’s cell therapy field.

The signing of this scientific research cooperation agreement is not only an important strategic collaboration between the two parties in scientific research and technological development, but will also have a profound impact on the development of China's medical and health care industry. In the future, both sides will continue to deepen their cooperation, work together, and contribute more to the advancement of medical technology in China and even globally.。

About Enka Saiyao

NK CellTech

Exterior of Enka Saiya Company

Shanghai Enke Cell Technology Co., Ltd. (Enke Therapeutics) is a biotechnology company focusing on the development of innovative NK cell therapy technologies. Based on over 30 years of the team's exploration in NK cell basic biology, preclinical and clinical translational research, Enke Therapeutics is committed to becoming a world-leading cell therapy company with deep expertise in NK cell therapy and its cutting-edge technologies.

Enkaipharma possesses exclusive allogeneic peripheral bloodNKCell Expansion and Cryopreservation for Clinical "Off-the-Shelf" GradeABCDE-NK^®Industrial Production Platform(Single Blood Supply OnceNKCell yield can reach trillions.)Based on, withNKCell-specific recognition of tumor receptors/Ligand Target Mining Technology(NKR-NK^TM)Relying on, Through logic gate gene circuits and other synthetic immunology chassis technologies (SynNK^TM), to achieveNKCellular Pluripotency-Intelligentization-Controllable gene editing, enabling precise targeting of cancer cells, precise adaptation to the tumor microenvironment, and precise matching of donor-recipient effects./Target cells.2024Year, Enkaiphar has2IndividualNKCell products have successively obtained approval in the United StatesFDAAnd ChinaCDEClinical Trial(IND)Permission.

Enkai Cell Medicine will focus on addressing the treatment challenges of major clinical diseases (such as cancer, autoimmune diseases, aging and degenerative diseases, immunodeficiency and related conditions), with the goal of achieving precise immunotherapy. It has developed a series of original intelligent NK cell products, striving to build an immune cell drug company that continuously breaks through core technologies and maintains international leadership, and aims to become a global source of next-generation NK cell therapy technologies and products.

(If any copyright issues arise, please contact the backend, and we will handle it immediately.)